Loading…

Pharvaris N.V.PHVSCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops oral bradykinin receptor antagonists to treat hereditary angioedema attacks.

Momentum neutral 52
Mkt cap
$2.21B
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$17.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
141 days
8 Apr 2027
Close · USD$31.55
1D-2.3%
1W-7.7%
1M+2.1%
3M-13.3%
6M+7.1%
YTD+13.7%
1Y+26.6%
ATR %4.9%
Beta0.81
52w lowhigh27.1% off high

What Pharvaris does

Develops oral bradykinin receptor antagonists to treat hereditary angioedema attacks.

Has no product on the market yet, so it earns no sales and is funded by money raised from investors. Dutch-incorporated, with research and operations in Switzerland and the Netherlands. Its drug is a pill taken at the start of an attack, so convenience is its main differentiator.

Products and services

  • Deucrictibant (oral HAE, on-demand and prophylaxis)

Customers

  • Allergists/immunologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Hereditary angioedema therapeutics

What could go right

  • Oral convenience advantage over injectables
  • HAE market with high unmet need

What could go wrong

  • Competitive HAE treatment landscape
  • Clinical and regulatory timeline risk

Moat: none (IP / patents). Differentiated oral mechanism vs injectable HAE standards, but still clinical-stage with no approved product.

Headquarters: Zug, Switzerland · Founded: 2018 · Employees: 129

Named competitors

Pharvaris at a glance

Size Pharvaris (PHVS) is a United States Health Care company (Biotechnology) with a market value of $2.21B, the 1710th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.55 on 18 Nov 2026.

Performance Over six months the shares gained 7.1%, against -11.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.

Short interest Short interest is 3.6% of the free float (30 Oct 2026).

Next results Next results expected around 8 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026PHVS 103Peer median 90
Six months, rebased to 100: Pharvaris against the median of its 20 peers (local-currency closes).

Pharvaris financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$559,350-$472,144-$291,583-$278,442-$160,737
EBITDA-$223M-$191M-$157M-$104M-$91.0M
Net income-$210M-$198M-$145M-$109M-$80.2M
Free cash flow-$192M-$155M-$131M-$101M-$70.7M
Capital expenditure$91,920$185,785$582,043$97,283$130,632
Total debt$685,980$912,310$892,052$263,906$466,198

Quarterly statements and history in the cockpit →

Pharvaris competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%302440VIMIANBEAMLKFTCLDXRCUSZEALPVLA300676ALMR300255IMNMTRVIMRVIXNCRPHVS6-month return →1-month return →
Up and to the right = strong over both horizons. Pharvaris is the large dot.

Pharvaris competitors and peer comparison

Head to head with its named competitors (PHVS vs BCRX vs IONS vs 4502.T)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Pharvaris PHVS$2.21B+7%n/an/an/an/a
BioCryst Pharmaceuticals BCRX$1.88B-16%+60%42%2.4×-11.0%
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%3.2×3.7%
Pharming PHARM.AS$867M-6%+2%9%2.2×2.4%

How Pharvaris compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pharvaris against its 20 peers (data as of 18 Nov 2026)
MeasurePHVSPeer medianRank in peer set
1-month return+2.1%-7.7%9th highest of 21
6-month return+7.1%-11.6%7th highest of 20
Distance from 52-week high-27.1%-38.3%8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a

Questions

Who are Pharvaris's main competitors?
Named competitors: BioCryst Pharmaceuticals (BCRX), CSL Behring (private or unlisted), KalVista Pharmaceuticals (private or unlisted), Ionis Pharmaceuticals (IONS), Takeda (4502.T), Pharming Group (PHARM.AS). The cockpit's measured peer set (industry) also includes SKBS (302440.KS), Vimian (VIMIAN.ST), Beam Therapeutics (BEAM), Lakefront Biotherapeutics (LKFT.AS), Celldex Therapeutics (CLDX), Arcus Biosciences (RCUS).
How has Pharvaris stock performed?
Over six months to 18 Nov 2026 the shares returned +7.1% against -11.6% for the median peer; over one year +26.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.